Immuneering Stock (NASDAQ:IMRX)
Previous Close
$1.29
52W Range
$1.00 - $3.83
50D Avg
$1.60
200D Avg
$1.75
Market Cap
$44.86M
Avg Vol (3M)
$238.10K
Beta
-0.26
Div Yield
-
IMRX Company Profile
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
IMRX Performance
Peer Comparison
| Ticker | Company |
|---|---|
| GOSS | Gossamer Bio, Inc. |
| ELVN | Enliven Therapeutics, Inc. |
| CMPX | Compass Therapeutics, Inc. |
| KRON | Kronos Bio, Inc. |
| PMVP | PMV Pharmaceuticals, Inc. |
| LYRA | Lyra Therapeutics, Inc. |
| CELC | Celcuity Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| NAMS | NewAmsterdam Pharma Company N.V. |
| IVA | Inventiva S.A. |
| LRMR | Larimar Therapeutics, Inc. |
| REPL | Replimune Group, Inc. |
| CNTA | Centessa Pharmaceuticals plc |
| CGEM | Cullinan Oncology, Inc. |
| IKNA | Ikena Oncology, Inc. |
| NVCT | Nuvectis Pharma, Inc. |